| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Physiological Sciences, University of Florida, Gainesville, Florida 32610
Address all correspondence and requests for reprints to: Thomas J. Wronski, Ph.D., Department of Physiological Sciences, Box 100144, JHMHC, University of Florida, Gainesville, Florida 32610. E-mail: wronskit{at}mail.vetmed.ufl.edu
The purpose of this study was to characterize the bone anabolic effects of basic fibroblast growth factor (bFGF) in ovariectomized (OVX) rats. Female Sprague Dawley rats were subjected to ovariectomy or sham surgery at 3 months of age and maintained untreated for 2 months post surgery. Groups of OVX rats were then treated iv with bFGF at doses of 100 or 200 µg/kg·day for 7 or 14 days. Another group of OVX rats and a group of sham-operated control rats were treated iv with vehicle alone for 14 days. Certain groups of bFGF-treated OVX rats were killed at 7 or 14 days after withdrawal of treatment. The right tibiae were processed undecalcified for quantitative bone histomorphometry. Vehicle-treated OVX rats were characterized by decreased cancellous bone volume associated with increased bone turnover. Treatment of OVX rats with bFGF strongly stimulated bone formation, as indicated by marked increases of at least a factor of 10 in osteoblast surface, osteoid surface, and osteoid volume. Furthermore, new osteoid spicules were observed within the marrow cavity of these animals. Osteoclast surface was markedly decreased in bFGF-treated OVX rats, but this finding may be secondary to the extensive osteoid surface. The strongest bone anabolic effects occurred in OVX rats treated with the higher dose of bFGF for 14 days, but these animals exhibited a bone mineralization defect, as evidenced by abundant osteoid and a lack of double fluorochrome labeling, despite markedly increased osteoblast surface. However, the newly-formed osteoid rapidly calcified after withdrawal of bFGF treatment. The data indicate that bFGF not only stimulates bone formation on pre-existing bone surfaces but also induces de novo formation of bone spicules within the marrow cavity, which results in partial restoration of lost cancellous bone mass in osteopenic OVX rats after only 14 days of treatment with the growth factor. These findings suggest that bFGF merits consideration for development as a potential treatment for patients with severe osteopenia who are unresponsive to conventional osteoporosis therapies.
This article has been cited by other articles:
 |
|
 |
|
  P. Simic, J. B. Culej, I. Orlic, L. Grgurevic, N. Draca, R. Spaventi, and S. Vukicevic Systemically Administered Bone Morphogenetic Protein-6 Restores Bone in Aged Ovariectomized Rats by Increasing Bone Formation and Suppressing Bone Resorption J. Biol. Chem., September 1, 2006; 281(35): 25509 - 25521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.T. Franceschi Biological Approaches to Bone Regeneration by Gene Therapy J. Dent. Res., December 1, 2005; 84(12): 1093 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hou, K. Adriane, and P. K. Feng Bone in Growth in bFGF Versus BMP Combined with bFGF Saturated PLA-PEG-PLA: Experiment in Surgically Created Rabbit Mandibular Defects Journal of Bioactive and Compatible Polymers, September 1, 2005; 20(5): 455 - 474. [Abstract] [PDF]
|
|
|
|
 |
|
 H. L. Wamsley, U. T. Iwaniec, and T. J. Wronski Selected Extraskeletal Effects of Systemic Treatment with Basic Fibroblast Growth Factor in Ovariectomized Rats Toxicol Pathol, August 1, 2005; 33(5): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Qiao, P. Shapiro, R. Kumar, and A. Passaniti Insulin-like Growth Factor-1 Regulates Endogenous RUNX2 Activity in Endothelial Cells through a Phosphatidylinositol 3-Kinase/ERK-dependent and Akt-independent Signaling Pathway J. Biol. Chem., October 8, 2004; 279(41): 42709 - 42718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Tumia and A. J. Johnstone Promoting the Proliferative and Synthetic Activity of Knee Meniscal Fibrochondrocytes Using Basic Fibroblast Growth Factor In Vitro Am. J. Sports Med., June 1, 2004; 32(4): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Liu, L. Malaval, and J. E. Aubin Global amplification polymerase chain reaction reveals novel transitional stages during osteoprogenitor differentiation J. Cell Sci., May 1, 2003; 116(9): 1787 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Xiao, D. Jiang, R. Gopalakrishnan, and R. T. Franceschi Fibroblast Growth Factor 2 Induction of the Osteocalcin Gene Requires MAPK Activity and Phosphorylation of the Osteoblast Transcription Factor, Cbfa1/Runx2 J. Biol. Chem., September 20, 2002; 277(39): 36181 - 36187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. T. Iwaniec, Li. Mosekilde, N. G. Mitova-Caneva, J. S. Thomsen, and T. J. Wronski Sequential Treatment with Basic Fibroblast Growth Factor and PTH Is More Efficacious than Treatment with PTH Alone for Increasing Vertebral Bone Mass and Strength in Osteopenic Ovariectomized Rats Endocrinology, July 1, 2002; 143(7): 2515 - 2526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kawaguchi, K. Nakamura, Y. Tabata, Y. Ikada, I. Aoyama, J. Anzai, T. Nakamura, Y. Hiyama, and M. Tamura Acceleration of Fracture Healing in Nonhuman Primates by Fibroblast Growth Factor-2 J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 875 - 880. [Abstract] [Full Text]
|
|
|
|
|
|
E. Shimizu-Sasaki, M. Yamazaki, S. Furuyama, H. Sugiya, J. Sodek, and Y. Ogata Identification of a Novel Response Element in the Rat Bone Sialoprotein (BSP) Gene Promoter that Mediates Constitutive and Fibroblast Growth Factor 2-induced Expression of BSP J. Biol. Chem., February 16, 2001; 276(8): 5459 - 5466. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
